Our analyses of survival outcomes showed that among patients undergoing up-front surgery, the five-year survival rates in the patients developing grade 0/1/2 during AC ( n = 41), patients developing grade 3/4 during AC ( n = 13), and patients who did not receive AC ( n = 17) were 25.3%, 20.5%, and 6.7%, respectively, with a borderline significant difference between the group that developed grade 0/1/2 AEs during AC and the no-AC group.
← all excerpts
Neoadjuvant and Adjuvant Chemotherapy for Pancreatic Adenocarcinoma: Literature Review and Our Experience of NAC-GS.
1
—
—